| Sep 6 |
Royalty Pharma plc's (NASDAQ:RPRX) Stock Is Rallying But Financials Look Ambiguous: Will The Momentum Continue?
|
| Sep 4 |
Rare Disease-Focused Ascendis Pharma Stock Falls On Underwhelming Q2 Earnings, Guidance Cut
|
| Sep 3 |
Ascendis and Royalty Pharma enter into $150M royalty funding agreement
|
| Sep 3 |
Royalty Pharma and Ascendis Pharma Enter Into $150 Million Royalty Funding Agreement
|
| Sep 3 |
Ascendis Pharma and Royalty Pharma Enter into $150 Million Royalty Funding Agreement
|
| Aug 28 |
Royalty Pharma to Present at Morgan Stanley’s 22nd Annual Global Healthcare Conference
|
| Aug 26 |
Jim Cramer on Royalty Pharma plc (NASDAQ:RPRX): It’s Been a ‘Bit of a Bust, I Feel Badly’
|
| Aug 22 |
Royalty Pharma plc Q2: Beat And Raise Reaffirm Our Buy Rating
|
| Aug 17 |
Why Is Royalty Pharma plc (RPRX) the Best Defensive Stock to Buy Now?
|
| Aug 16 |
Jim Cramer: This Financial Stock Is A Buy, Core Scientific Is A 'Very Overvalued Situation'
|
